Global Cancer Early Detection and Diagnosis 麻豆原创 Research Report 2025

Publication ID:

PB504258927

Publication Date:

May 2, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Cancer Early Detection and Diagnosis was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Cancer early detection and diagnosis are crucial in improving treatment outcomes and patient survival rates. Early detection involves identifying cancer at its earliest stages, even before symptoms become apparent.
North American market for Cancer Early Detection and Diagnosis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Cancer Early Detection and Diagnosis is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Cancer Early Detection and Diagnosis in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Cancer Early Detection and Diagnosis include Exact Sciences, Grail, Genetron Health, New Horizon Health, Burning Rock, Berry Oncology, Shanghai Kunyuan Biotechnology, Oncognostic, Epigenomics, Abbott, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Early Detection and Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Early Detection and Diagnosis.
The Cancer Early Detection and Diagnosis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Early Detection and Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Early Detection and Diagnosis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Exact Sciences
Grail
Genetron Health
New Horizon Health
Burning Rock
Berry Oncology
Shanghai Kunyuan Biotechnology
Oncognostic
Epigenomics
Abbott
Qiagen
iStat Biomedical
Segment by Type
Colorectal Cancer
Liver Cancer
Lung Cancer
Other
Segment by Application
Hospital
Medical Center
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Early Detection and Diagnosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cancer Early Detection and Diagnosis 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Colorectal Cancer
1.2.3 Liver Cancer
1.2.4 Lung Cancer
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Cancer Early Detection and Diagnosis 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Early Detection and Diagnosis 麻豆原创 Perspective (2020-2031)
2.2 Global Cancer Early Detection and Diagnosis Growth Trends by Region
2.2.1 Global Cancer Early Detection and Diagnosis 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cancer Early Detection and Diagnosis Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Cancer Early Detection and Diagnosis Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Cancer Early Detection and Diagnosis 麻豆原创 Dynamics
2.3.1 Cancer Early Detection and Diagnosis Industry Trends
2.3.2 Cancer Early Detection and Diagnosis 麻豆原创 Drivers
2.3.3 Cancer Early Detection and Diagnosis 麻豆原创 Challenges
2.3.4 Cancer Early Detection and Diagnosis 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Early Detection and Diagnosis Players by Revenue
3.1.1 Global Top Cancer Early Detection and Diagnosis Players by Revenue (2020-2025)
3.1.2 Global Cancer Early Detection and Diagnosis Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Cancer Early Detection and Diagnosis 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cancer Early Detection and Diagnosis Revenue
3.4 Global Cancer Early Detection and Diagnosis 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Early Detection and Diagnosis 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Early Detection and Diagnosis Revenue in 2024
3.5 Global Key Players of Cancer Early Detection and Diagnosis Head office and Area Served
3.6 Global Key Players of Cancer Early Detection and Diagnosis, Product and Application
3.7 Global Key Players of Cancer Early Detection and Diagnosis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Early Detection and Diagnosis Breakdown Data by Type
4.1 Global Cancer Early Detection and Diagnosis Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Cancer Early Detection and Diagnosis Forecasted 麻豆原创 Size by Type (2026-2031)
5 Cancer Early Detection and Diagnosis Breakdown Data by Application
5.1 Global Cancer Early Detection and Diagnosis Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Cancer Early Detection and Diagnosis Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Cancer Early Detection and Diagnosis 麻豆原创 Size (2020-2031)
6.2 North America Cancer Early Detection and Diagnosis 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2020-2025)
6.4 North America Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Early Detection and Diagnosis 麻豆原创 Size (2020-2031)
7.2 Europe Cancer Early Detection and Diagnosis 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2020-2025)
7.4 Europe Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Early Detection and Diagnosis 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Cancer Early Detection and Diagnosis 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cancer Early Detection and Diagnosis 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Cancer Early Detection and Diagnosis 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Early Detection and Diagnosis 麻豆原创 Size (2020-2031)
9.2 Latin America Cancer Early Detection and Diagnosis 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Early Detection and Diagnosis 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Cancer Early Detection and Diagnosis 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Cancer Early Detection and Diagnosis 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Exact Sciences
11.1.1 Exact Sciences Company Details
11.1.2 Exact Sciences Business Overview
11.1.3 Exact Sciences Cancer Early Detection and Diagnosis Introduction
11.1.4 Exact Sciences Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.1.5 Exact Sciences Recent Development
11.2 Grail
11.2.1 Grail Company Details
11.2.2 Grail Business Overview
11.2.3 Grail Cancer Early Detection and Diagnosis Introduction
11.2.4 Grail Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.2.5 Grail Recent Development
11.3 Genetron Health
11.3.1 Genetron Health Company Details
11.3.2 Genetron Health Business Overview
11.3.3 Genetron Health Cancer Early Detection and Diagnosis Introduction
11.3.4 Genetron Health Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.3.5 Genetron Health Recent Development
11.4 New Horizon Health
11.4.1 New Horizon Health Company Details
11.4.2 New Horizon Health Business Overview
11.4.3 New Horizon Health Cancer Early Detection and Diagnosis Introduction
11.4.4 New Horizon Health Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.4.5 New Horizon Health Recent Development
11.5 Burning Rock
11.5.1 Burning Rock Company Details
11.5.2 Burning Rock Business Overview
11.5.3 Burning Rock Cancer Early Detection and Diagnosis Introduction
11.5.4 Burning Rock Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.5.5 Burning Rock Recent Development
11.6 Berry Oncology
11.6.1 Berry Oncology Company Details
11.6.2 Berry Oncology Business Overview
11.6.3 Berry Oncology Cancer Early Detection and Diagnosis Introduction
11.6.4 Berry Oncology Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.6.5 Berry Oncology Recent Development
11.7 Shanghai Kunyuan Biotechnology
11.7.1 Shanghai Kunyuan Biotechnology Company Details
11.7.2 Shanghai Kunyuan Biotechnology Business Overview
11.7.3 Shanghai Kunyuan Biotechnology Cancer Early Detection and Diagnosis Introduction
11.7.4 Shanghai Kunyuan Biotechnology Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.7.5 Shanghai Kunyuan Biotechnology Recent Development
11.8 Oncognostic
11.8.1 Oncognostic Company Details
11.8.2 Oncognostic Business Overview
11.8.3 Oncognostic Cancer Early Detection and Diagnosis Introduction
11.8.4 Oncognostic Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.8.5 Oncognostic Recent Development
11.9 Epigenomics
11.9.1 Epigenomics Company Details
11.9.2 Epigenomics Business Overview
11.9.3 Epigenomics Cancer Early Detection and Diagnosis Introduction
11.9.4 Epigenomics Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.9.5 Epigenomics Recent Development
11.10 Abbott
11.10.1 Abbott Company Details
11.10.2 Abbott Business Overview
11.10.3 Abbott Cancer Early Detection and Diagnosis Introduction
11.10.4 Abbott Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.10.5 Abbott Recent Development
11.11 Qiagen
11.11.1 Qiagen Company Details
11.11.2 Qiagen Business Overview
11.11.3 Qiagen Cancer Early Detection and Diagnosis Introduction
11.11.4 Qiagen Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.11.5 Qiagen Recent Development
11.12 iStat Biomedical
11.12.1 iStat Biomedical Company Details
11.12.2 iStat Biomedical Business Overview
11.12.3 iStat Biomedical Cancer Early Detection and Diagnosis Introduction
11.12.4 iStat Biomedical Revenue in Cancer Early Detection and Diagnosis Business (2020-2025)
11.12.5 iStat Biomedical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Exact Sciences
Grail
Genetron Health
New Horizon Health
Burning Rock
Berry Oncology
Shanghai Kunyuan Biotechnology
Oncognostic
Epigenomics
Abbott
Qiagen
iStat Biomedical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.